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ChemotherapyObjective. To determine the primary remission rates and predictors of drug resistance in patients with post-
molar low-risk gestational trophoblastic neoplasia (GTN) who were treated with a 5-day intramuscular metho-
trexate (5-day IM MTX) or a 5-day drip infusion etoposide (5-day DIV ETP) regimen.
Methods. Between 1980 and 2014, 166 consecutive patients with low-risk post-molar GTN were initially
treatedwith a 5-day IMMTX or a 5-dayDIV ETP regimen. The primary remission rates, changes in chemotherapy
due to drug resistance or toxicity, and relapse rates were compared. Furthermore, we analyzed the factors that
inﬂuenced the development of resistance to MTX.
Results. Primary remission rates were signiﬁcantly higher among the ETP-treated patients than among the
MTX-treated patients. Among the 42 patients who required a change in chemotherapy, 23 patients (22.6%)
and 4 patients (6.3%)were diagnosed as being resistant toMTX and EPT, respectively. Maternal age and the pres-
ence of metastasis did not signiﬁcantly inﬂuence the development of MTX resistance, although higher FIGO
scores and pre-treatment human chorionic gonadotropin (hCG) levels of N5 × 104 mIU/mL were signiﬁcantly
more common among patients who developed MTX resistance. Moreover, a b30% decrease in hCG after the
ﬁrst cycles of MTX chemotherapy was signiﬁcantly associated with the development of MTX resistance.
Conclusions. All patients with low-risk GTN eventually achieved complete remission, although several pa-
tients developed drug resistance to the ﬁrst-line chemotherapy. A b30% decrease in hCG during the ﬁrst chemo-
therapy cycle may be an early indicator of drug resistance after commencing a 5-day MTX regimen.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Gestational trophoblastic neoplasia (GTN) is extremely responsive
to chemotherapy, and almost all patientswith low-risk GTN can achieve
remission. The most common and effective chemotherapy regimens for
patients with low-risk GTN are 5-day intramuscular methotrexate (5-
day IM MTX), 8-day alternating intramuscular MTX and folinic acid& Gynecology, Tokyo Women's
, Japan.
.(MTX-FA), 5-day intravenous actinomycin-D (5-day Act-D), and 5-day
drip infusion etoposide (5-day DIV ETP) [1–4]. The most popular ﬁrst-
line treatment for patients with low-risk GTN is a MTX regimen with
or without folinic acid rescue, due to its favorable safety and toxicity
proﬁles, such as the reduced risk of alopecia, ovarian dysfunction, and
second malignancies. However, approximately one-quarter of patients
with low-risk GTNwho are treated withMTX have to change their che-
motherapy regimen due to the development of drug resistance or intol-
erable toxicity [1–4]. Although almost all primary treatment failures in
these cases are successfully salvagedwith another single-agent or com-
bination chemotherapy, the change to a second-line chemotherapy
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reduce the patient's quality of life. Moreover, salvage treatment with a
combination chemotherapy that contains ETP causes alopecia, is associ-
ated with an earlier onset of menopause, and may slightly increase the
risk of developing secondary malignancies [5].
In this study, we retrospectively compared the primary remission
and relapse rates among patients with low-risk GTN who were treated
with 5-day IM MTX or 5-day DIV ETP. Furthermore, we analyzed the
risk factors for developing drug resistance in low-risk GTN patients
who were treated with a 5-day IM MTX regimen.
2. Patients and methods
Between 1980 and 2014, 268 patients with post-molar FIGO stages
I–III GTN(scores of b7) were treated at Chiba University (1980–2009)
and TokyoWomen's University (2010–2014). The design for this retro-
spective study was reviewed and approved by our institutional ethics
review board. The pre-treatment evaluation of each patient included a
complete history and physical examination, complete blood count,
renal and liver function tests, serum human chorionic gonadotropin
(hCG) levels, pelvic ultrasonography, and chest radiography and/or
lung computed tomography. Serum hCG levels were evaluated before
each chemotherapy cycle and twice per week during the chemotherapy
cycle. We excluded 102 patients from this analysis due to combined
planned hysterectomy and chemotherapy (72 patients), initial treat-
ment with several kinds of combination chemotherapy (13 patients),
and other non-MTX/non-ETP single-agent regimens (MTX-FA: 12 pa-
tients, 5-day Act-D: 5 patients). The remaining 166 patients (61.9%)
were started on 5-day IMMTX (102 patients) or 5-day DIV ETP (64 pa-
tients) (Table 1).
Because there is no international consensus deﬁnition for drug resis-
tance to ﬁrst-line chemotherapy for GTN, patients were deﬁned as de-
veloping drug resistance if they had a b50% decrease in their hCG
levels for ≥2 consecutive cycles of chemotherapy, or if they experienced
an increase in hCG levels for 1 week. Drug toxicity proﬁles were classi-
ﬁed according to the Common Terminology Criteria for Adverse Events
(version 4.0) [6]. Caseswith at least grade 3 stomatitis, at least a grade 2
increase in aspartate aminotransferase levels, or at least grade 1 skin
rash (macules, papules) were diagnosed as having drug toxicity, and
their chemotherapy regimen was changed. Primary remission was de-
ﬁned as three consecutive weekly hCG levels that were within the nor-
mal range using the same chemotherapy regimen.
All data are reported asmean± standard deviation,median (range),
or number (%). Continuous data were examined for skewness (a mea-
sure of symmetry) and kurtosis (whether data are peaked or ﬂat, com-
pared to a normal distribution) using JMP Pro software (version 11.2.0;
SAS, Inc., Japan, Tokyo). Pre-treatment hCG levels did not ﬁt a GaussianTable 1
The characteristics of 166 patients with low-risk gestational trophoblastic neoplasia who
were treated with 5-day methotrexate and 5-day etoposide.
MTX (n = 102) ETP (n = 64) P-value
Age, years (mean ± SD) 32.4 ± 7.4 29.4 ± 7.1 0.01
FIGO stage, n
I 70 39
II 1 0
III 31 25 NS
FIGO score (mean ± SD) 2.1 ± 1.2 2.4 ± 1.5 NS
b5 98 55
≥5 4 9 0.02
Median pre-treatment hCG,
mIU/mL (range)
4000
(1.4–640,000)
7500
(7.2–1,875,200)
NS
hCG N 105 mIU/mL, n (%) 6(5.9) 9(14.1) NS
hCG N 104 mIU/mL, n (%) 37(36.3) 27(42.1) NS
MTX: methotrexate, ETP: etoposide, SD: standard deviation, FIGO: International Federa-
tion of Gynecology and Obstetrics, hCG: human chorionic gonadotropin, NS: no signiﬁcant
difference.distribution, and were analyzed using the Mann–Whitney U test for
inter-group comparisons. Proportional data were analyzed using
Fisher's exact test. Differences with a p-value of b0.05 were considered
statistically signiﬁcant.
3. Results
The characteristics of the 166 patients with low-risk GTN who were
treated with 5-day IM MTX or 5-day DIV ETP are shown in Table1. The
patients' ages were 32.4 ± 7.4 years and 29.4 ± 7.1 years, respectively
(p = 0.01). Metastatic disease was present in 32 patients (31.4%) in
theMTX group (one vaginal wall and 31 lungmetastases) and in 25 pa-
tients (39.1%) in the ETP group (one vaginal wall and lung metastases
and 24 lung metastases) (p = 0.37). All of these metastatic tumors
were b3 cm and the numbers of lung metastases were ≤4, except for
those in one patient. That patient had 8 lung metastatic foci and devel-
oped drug resistance to 5-day DIV ETP. The MTX and ETP groups' FIGO
scores were 2.1 ± 1.2 and 2.4 ± 1.5, respectively (p = 0.12), although
signiﬁcantly more patients in the ETP group had a score of ≥5 (p =
0.02). The MTX and ETP groups' median pre-treatment hCG levels
were 4000 mIU/mL and 7500 mIU/mL, respectively (p = 0.12). Pre-
treatment hCG levels of N105 mIU/mL were observed in six patients
(5.9%) who were treated with MTX and in 9 patients (14.1%) who
were treated with ETP (p = 0.07).
The primary remission and relapse rates for patients who were
treated with 5-day IM MTX or 5-day DIV ETP are shown in Table 2.
The primary remission rates for patients who were treated with MTX
(64.7%) and ETP (90.6%) were signiﬁcantly different (p b 0.0001).
Thirty-six patients (35.3%) who were treated with MTX required a
change in regimen due to developing drug resistance (n = 23) and
drug toxicities (n=13). The drug toxicities forMTXwere severe stoma-
titis (≥grade 3: 4 patients), deteriorating aspartate aminotransferase
levels (≥grade 2: 5 patients), and skin rash (≥grade 1: 4 patients);
grades 3–4 leukocytopenia, thrombocytopenia, and anemia were not
observed in this series. In contrast, only 6 patients who were treated
with ETP required a change in regimen due to the development of
drug resistance (4 patients) and drug toxicities (2 patients). The drug
toxicities for ETP were skin rash (grade 1) and deteriorating aspartate
aminotransferase levels (grade 2). When we compared the MTX and
ETP groups, we observed signiﬁcant differences in the frequencies of
drug resistance (22.6% vs. 6.3%, p = 0.006) and drug toxicity (12.7%
vs. 3.1%, p = 0.04).
After primary remission was achieved using 5-day IM MTX, 2 pa-
tients relapsed at 4months and 5months, after their last chemotherapy
cycle. These 2 relapsed patients were successfully re-treated with ETP-
containing combination chemotherapy [7]. Another patient who was
initially treated with 5-day DIV ETP also relapsed. After 7 cycles of 5-
day DIV ETP, she developed drug resistance and the regimen was
changed to a combined ETP and Act-D regimen to achieve remission.
However, she relapsed at 5 months after the last chemotherapy cycle.
This patient was also successfully re-treated with ETP-containing com-
bination chemotherapy [7].
Among the 102 patients with low-risk GTN who were treated with
5-day IMMTX, 23 patients had to change the initial chemotherapy reg-
imen due to the development of drug resistance. Therefore, we com-
pared the factors that might inﬂuence the development of drugTable 2
Primary remission rates, drug resistant rates, and relapse rates.
5-day MTX (n = 102) 5-day ETP (n = 64) P-value
Primary remission 66 (64.7%) 58 (90.6%) b0.0001
Regimen change due to:
Drug resistance 23 (22.6%) 4 (6.3%) 0.006
Drug toxicity 13 (12.7%) 2 (3.1%) 0.04
Relapse 2 (2.0%) 1 (1.6%) NS
MTX: methotrexate, ETP: etoposide, NS: no signiﬁcant difference.
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resistant group (n= 79; primary remission: 66 patients; drug toxicity:
13 patients) (Table 3). We did not observe any signiﬁcant differences
between the two groups in maternal age (p = 0.21) and the presence
of metastases (p = 0.74). In contrast, the median pre-treatment hCG
levels in the drug resistant group (16,000 mIU/mL, 85.8–256,000 mIU/
mL) were signiﬁcantly higher than those in the non-drug resistant
group (2000 mIU/mL, 1.4–640,000 mIU/mL) (p = 0.0004). Although
we only identiﬁed a small number of cases with elevated pre-
treatment hCG levels, a pre-treatment hCG level of ≥105 mIU/mL did
not signiﬁcantly inﬂuence the development of drug resistance (p =
0.09). The FIGO scores in the drug resistant group (2.8 ± 1.3) were sig-
niﬁcantly higher than those in the non-drug resistant group (1.8 ± 1.1)
(p = 0.0006).
After commencing the 5-day IM MTX regimen, weekly serum hCG
decreaseswere calculatedduring theﬁrst and second chemotherapy cy-
cles. In the ﬁrst cycle, the hCG percentage decrease in the drug resistant
group (21.9 ± 24.8%) was signiﬁcantly lower than that in the non-drug
resistant group (38.3 ± 14.6%) (p b 0.0001). During the second chemo-
therapy cycle, the frequency of hCG decreases was also signiﬁcantly
lower in the drug resistant group (p = 0.0012). Moreover, among the
23 patients with drug resistance, 17 patients (73.9%) were diagnosed
as being drug resistantwithin 5 cycles (median: 3 cycles, range: 1–5 cy-
cles), and the remaining 6 patients were diagnosed as being drug resis-
tant at a later time (median: 8 cycles, range: 6–9 cycles). The
frequencies of hCG decreases in the early drug resistant group (17.4 ±
27.1%) were signiﬁcantly lower (p = 0.0005) than those in the late
drug resistant group (34.8 ± 9.2%) and the non-drug resistant group
(38.3 ± 14.6%) (data not shown).
The drug resistant group had a signiﬁcantly higher median number
of chemotherapy cycles that was needed to achieve remission (8.8 cy-
cles, 4–19 cycles), compared to the non-drug resistant group (4.7 cycles,
2–9 cycles) (p b 0.0001).
4. Discussion
The cure rates for low-risk GTN have approached 100%, even in the
presence of metastasis, higher pre-treatment hCG levels, and higher
FIGO scores (5–6 points) with effective chemotherapy regimen. Al-
though there is no clear international consensus regarding what is the
best single-agent therapy for low-risk GTN [8–9], a MTX regimen with
or without folinic acid rescue is preferred, due to its favorable safety
and toxicity proﬁles, such as the reduced risk of alopecia, ovarianTable 3
Risk factors for developing drug resistance.
5-day MTX P-value
Drug resistant
(n = 23)
Non-drug
resistant
(n = 79)
Age, years 34.1 ± 7.2 31.9 ± 7.4 NS
Metastatic GTN 6 (26.1) 26 (32.9) NS
Median pre-treatment hCG,
mIU/mL (range)
16,000
(85.8–256,000)
2000
(1.4–640,000)
0.0004
≥105 mIU/mL, n (%) 3 (13.0) 3 (3.8)
b105 mIU/mL, n (%)l 20(87.0) 76 (96.2) NS
≥5 × 104 mIU/mL, n (%) 6 (26.1) 4 (5.1)
b5 × 104 mIU/mL, n (%) 17 (73.9) 75 (94.9) 0.003
FIGO score 2.8 ± 1.3 1.8 ± 1.1 0.0006
Weekly hCG decreases, %
First cycle 21.9 ± 24.8 38.3 ± 14.6 b0.0001
b30% decrease 14 (60.9) 19 (24.0) 0.0012
Second cycle 21.3 ± 20.4 33.9 ± 2.0 0.0012
Median chemotherapy cycles
(range)
8.8 (4–19) 4.7 (2–9) b0.0001
MTX: methotrexate, GTN: etoposide, SD: standard deviation, FIGO: International Federa-
tion of Gynecology and Obstetrics, hCG: human chorionic gonadotropin, NS: no signiﬁcant
difference.dysfunction, and second malignancies [5]. Nevertheless, 11–31% of pa-
tients with low-risk GTN who are treated with MTX (with or without
folinic acid rescue) required a change in their chemotherapy regimen,
due to the development of drug resistance and/or intolerable toxicity.
These patients require second-line single-agent or ETP-containing com-
bination chemotherapy, and are typically successfully salvaged after this
treatment [1–4]. However, this change in regimen undoubtedly in-
creases the total duration and cost of treatment, and potentially reduces
the patient's quality of life [10]. Therefore, it would be useful to identify
patients with low-risk GTN who will develop drug resistance to MTX.
In their study of a 5-day IMMTX regimen for patients with low-risk
GTN, Soper et al. [11] reported that primary remission was achieved in
60% (31/52) of their patients, although 21 patients required second-
line chemotherapy due to the development of drug resistance (10 pa-
tients) and drug toxicity (11 patients). They also found that high pre-
treatment hCG levels (N10,000 mIU/mL) were associated with the
development of drug resistance. Lurain et al. [4] have also reported a
primary remission rate of 89.3% (226/253), with 27 patients (10.7%) de-
veloping resistance toMTX. In this context, the factors that are associat-
edwith the development ofMTX resistance are pretreatment hCG levels
of N50,000 mIU/mL, non-molar antecedent pregnancy, and a clinico-
pathological diagnosis of choriocarcinoma. We have also previously re-
ported that the 5-day IM MTX regimen for patients with low-risk GTN
provides a primary remission rate of 73.6% (89/121), although 7
(5.8%) and 25 (20.7%) patients required second-line chemotherapy
due to drug resistance and drug toxicities, respectively [3]. However,
caseswith a transient deterioration in aspartate aminotransferase levels
were over-judged as drug toxicities during that period (1974–1979).
In the present study, the antecedent pregnancy was hydatidiform
mole, the FIGO scores were ≤6 (median: 2, range: 0–6), and we exclud-
ed patients who underwent combined planned hysterectomy and che-
motherapy. Among the remaining patients, the primary remission rate
for 5-day IM MTX was 64.7% (66/102), and 23 patients (22.6%) had to
change their chemotherapy regimen due to drug resistance. Compared
to the 5-day DIV ETP regimen, theMTX primary remission rate was sig-
niﬁcantly lower and the MTX drug resistance rate was signiﬁcantly
higher. Nevertheless, ETP treatment can increase the risk of secondary
malignant tumors [5], and so ETP is currently considered unattractive
as a ﬁrst-line therapy.
We also analyzed the factors that inﬂuenced the development of
drug resistance in patients who were treated with 5-day IM MTX. Our
ﬁndings indicated that maternal age, the presence of metastasis, and
pre-treatment hCG levels of N105 mIU/mL did not inﬂuence the devel-
opment of drug resistance. However, these ﬁndings conﬂict with those
of previous reports [12–15]. Althoughwe only included a small number
of cases with high pre-treatment hCG levels, the median pre-treatment
hCG levels and frequency of pre-treatment hCG levels of ≥5 × 104 mIU/
mL were signiﬁcantly higher in the drug resistant group. The FIGO
scores were also signiﬁcantly higher in the drug resistant group,
which is similar to theﬁndings of other reports [16], although the differ-
ences in the FIGO scores between the drug resistant and non-drug resis-
tant groups were small for the predictors of developing drug resistance.
The drug resistant group also exhibited a signiﬁcantly lower frequency
of weekly hCG decreases, as well as a higher frequency of b30% de-
creases in hCG. The deﬁnite values for weekly hCG decreases in
predicting drug resistance were not estimated in this series, although
an approximately b 30% decrease in hCG during the ﬁrst cycle may be
a predictor of drug resistance to 5-day IMMTX. Although we only iden-
tiﬁed a small number of cases that were resistant to ETP, the frequency
of hCG decreases during the ﬁrst cycle was lower among the patients
who were resistant to ETP (17.6 ± 9.5%) than among the patients who
were not ETP resistant (31.4± 15.6%). In addition,multiple lungmetas-
tases and high FIGO scores were common in the drug resistant group
(data not shown).
In conclusion, the primary remission and drug resistant rates for the
5-day IM MTX regimen were signiﬁcantly poorer than the rates for 5-
432 S. Kizaki et al. / Gynecologic Oncology 139 (2015) 429–432day EIV ETP, although the ﬁrst-line use of MTX regimen is recommend-
ed, due to the possibility of harmful toxicities with ETP regimen. There-
fore, early prediction for developing MTX resistance may help improve
the management of patients with low-risk GTN. In this study, high
pre-treatment hCG levels, pre-treatment hCG levels of ≥5 × 104 mIU/
mL, high FIGO scores, and poor weekly hCG decreases during the ﬁrst
and second chemotherapy courses inﬂuenced the development of
MTX resistance. An approximately b 30% decrease in hCG during the
ﬁrst chemotherapy cycle may be an early indicator of drug resistance
after beginning a 5-day MTX regimen.
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